Online citations, reference lists, and bibliographies.
← Back to Search

Evaluation Of New Biomarkers In The Prediction Of Malignant Mesothelioma In Subjects With Environmental Asbestos Exposure

Melike Demir, H. Kaya, Mahşuk Taylan, A. Ekinci, Sureyya Yılmaz, F. Teke, C. Sezgi, A. C. Tanrıkulu, Fatih Meteroğlu, A. Şenyiğit
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
IntroductionThe purpose of this study was to investigate the potential value of certain biomarkers in predicting the presence of malignant pleural mesothelioma (MPM) in individuals environmentally exposed to asbestos.MethodsThis prospective study investigated three groups; a control group composed of 41 healthy subjects, an asbestos exposure group consisting of 48 individuals, and a MPM group consisting of 42 patients. Serum levels of soluble mesothelin-related peptide (SMRP), thioredoxin-1 (TRX), epidermal growth factor receptor (EGFR), fibulin-3, syndecan-1 (SDC-1), and mesothelin were determined.ResultsBenign pleural plaques were present in 27 (58.3 %) of the individuals in the asbestos exposure group. The asbestos exposure group had significantly higher mean TRX, SMRP, and mesothelin levels compared to the control group (p = 0.023, p = 0.011, and p < 0.001, respectively). Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002). Unlike the other biomarkers, SMRP and TRX levels increased in a graded fashion among the control, asbestos exposure, and MPM groups, respectively. Area under the curve values for SMRP and TRX were 0.86 and 0.72, respectively (95 % CI 0.79–0.92 and p < 0.001 for SMRP, and 95 % CI 0.62–0.81 and p < 0.001 for TRX). The cut-off value for SMRP was 0.62 nmol/l (sensitivity: 97.6 %, specificity: 68.9 %, positive predictive value (PPV): 56.2 %, and negative predictive value (NPV): 98.3 %) and for TRX was 156.67 ng/ml (sensitivity: 92.9 %, specificity: 77.6 %, PPV: 41.4 %, and NPV: 92.1 %). The combination of the biomarkers reached a sensitivity of 100 %, but had lower specificity (as high as 27.7 %).ConclusionsSerum biomarkers may be helpful for early diagnosis of MPM in asbestos-exposed cases. SMRP and TRX increased in a graded fashion from the controls to asbestos exposure and MPM groups. These two seem to be the most valuable biomarkers for the diagnosis of MPM, both individually and in combination.
This paper references
10.1371/journal.pone.0014816
Specific Syndecan-1 Domains Regulate Mesenchymal Tumor Cell Adhesion, Motility and Migration
F. Zong (2011)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions.
M. Metintas (1994)
10.1016/j.abb.2015.02.025
The paradoxical role of thioredoxin on oxidative stress and aging.
Geneva M. Cunningham (2015)
10.1007/s00408-013-9526-9
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
10.1097/JTO.0b013e31821e1c08
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
10.1152/AJPLUNG.1995.268.3.L471
Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals.
D. Kamp (1995)
10.3389/fonc.2013.00310
The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors
T. Szatmári (2013)
10.1083/JCB.108.4.1547
Molecular cloning of syndecan, an integral membrane proteoglycan
S. Saunders (1989)
10.1097/pdm.0b013e3182a3645e
Low Frequency of EGFR Mutations in Pleural Mesothelioma Patients, Cologne, Germany.
V. Schildgen (2014)
10.1159/000196364
Chromosome Analysis in Pleural Effusions
M. Metintas (1994)
10.1515/raon-2015-0019
Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
V. Kovač (2015)
10.1155/2014/419853
Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
Filip Mundt (2014)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1111/j.1440-1827.2006.02024.x
Molecular tumor markers for asbestos‐related mesothelioma: Serum diagnostic markers
M. Maeda (2006)
10.1634/THEONCOLOGIST.7-SUPPL_4-31
Epidermal growth factor receptor dependence in human tumors: more than just expression?
C. Arteaga (2002)
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
F. Ciardiello (2001)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
Syndecan-1 expression in different soft tissue tumours.
Z. Orosz (2001)
10.1016/j.exer.2009.09.018
Focus on molecules: fibulin-3 (EFEMP1).
Y. Zhang (2010)
10.1016/j.lungcan.2015.09.021
Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
L. Santarelli (2015)
10.1155/2014/902748
Oxidative Status and Acute Phase Reactants in Patients with Environmental Asbestos Exposure and Mesothelioma
C. Sezgi (2014)
10.1002/(SICI)1096-9896(1998110)186:3<300::AID-PATH180>3.0.CO;2-Q
Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome
S. Kumar-Singh (1998)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1186/1743-8977-11-24
Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation
Joyce K. Thompson (2014)
10.7314/APJCP.2015.16.4.1403
Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
H. Kaya (2015)
10.1016/j.lungcan.2010.01.002
Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
R. Gaafar (2010)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1164/AJRCCM-CONFERENCE.2012.185.1_MEETINGABSTRACTS.A1575
Clinical Significance Of Pleural Effusion Mesothelin In Malignant Pleural Mesothelioma
S. Yamada (2012)
10.1038/sj.embor.7400033
Fibulins: physiological and disease perspectives
W. Argraves (2003)
10.1146/annurev.biophys.30.1.421
Properties and biological activities of thioredoxins.
G. Powis (2001)
10.1080/01913120252959227
Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 Cases
V. Roggli (2002)
10.1111/j.1440-1843.2007.01187.x
Epidemiology of pleural mesothelioma in a population with non‐occupational asbestos exposure
M. Metintas (2008)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1097/MCG.0b013e31824e901b
Serum Thioredoxin-1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
C. Tabata (2013)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.3109/07357907.2012.749265
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
Colon cancer at the molecular level--usefulness of epithelial-mesenchymal transition analysis.
Ana-Maria Todosi (2012)
10.1515/CCLM.2010.165
Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population
Eun-Kee Park (2010)
10.1111/j.1742-4658.2009.07448.x
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
T. Mitsudomi (2010)
10.1093/mutage/ger020
Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis.
M. Tomasetti (2011)
10.3892/MCO.2013.175
Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.
K. Fukuoka (2013)
10.2486/INDHEALTH.46.484
Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure.
D. Pelclova (2008)



This paper is referenced by
10.20944/preprints201911.0117.v1
Identification of Malignant Mesothelioma Risk Factors through Association Rule Mining
Talha Mahboob Alam (2019)
Chapter 12 Biomarkers of Response to Asbestos Exposure
Blair ()
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.18632/oncotarget.14712
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
Dongxu Pei (2017)
10.2217/bmm-2018-0285
Fibulin-3 as biomarker of malignant mesothelioma.
C. Ledda (2019)
10.3390/ijerph17082636
Asbestos Air Pollution: Description of a Mesothelioma Cluster Due to Residential Exposure from an Asbestos Cement Factory
L. Vimercati (2020)
10.3390/cancers11060831
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma
A. Catino (2019)
10.1016/j.trecan.2016.07.004
Malignant Mesothelioma: Time to Translate?
A. Napolitano (2016)
10.1007/s00204-019-02594-4
Mild steel welding is associated with alterations in circulating levels of cancer-related proteins
A. Gliga (2019)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.1371/journal.pone.0214808
Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals
H. Yang (2019)
10.1016/j.shaw.2020.07.009
Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders
E. Park (2020)
10.3389/fonc.2020.00445
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
L. Ferrari (2020)
10.1007/s12079-017-0411-9
Sulfatase-1 knockdown promotes in vitro and in vivo aggressive behavior of murine hepatocarcinoma Hca-P cells through up-regulation of mesothelin
S. Mahmoud (2017)
10.1097/JOM.0000000000001211
Asbestos Exposures, Mesothelioma Incidence and Mortality, and Awareness by General Practitioners in the Molise Region, Central Italy
G. Ripabelli (2018)
10.21037/tlcr.2018.04.09
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Lisa Brusselmans (2018)
10.18632/oncotarget.12707
Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis
Ran Ren (2016)
10.1007/978-3-319-53560-9_12
Biomarkers of Response to Asbestos Exposure
C. Mesaros (2017)
10.1186/s12885-017-3375-5
Calretinin as a blood-based biomarker for mesothelioma
G. Johnen (2017)
10.1109/ICECCE49384.2020.9179443
Risk Factors Identification of Malignant Mesothelioma: A Data Mining Based Approach
Muhammad Latif (2020)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1016/j.jtho.2017.04.002
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
Semantic Scholar Logo Some data provided by SemanticScholar